Can patients with thrombocytopenia use avatrombopag long-term?

Whether avatrombopag can be used long-term in patients with thrombocytopenia is a complex issue that requires comprehensive consideration from multiple aspects.

Avatrombopag, especially its trade name Sucoxin (avatrombopag maleate tablets), is a thrombopoietin receptor agonist that can effectively stimulate the proliferation and differentiation of megakaryocytes in bone marrow cells, thereby promoting platelet production. This has a significant effect in treating thrombocytopenia. However, this drug is primarily used to treat thrombocytopenia associated with chronic liver disease in adults before elective invasive tests or surgeries to increase platelet counts and reduce the risk of bleeding.

While avatrombopag is excellent at raising platelet counts, long-term use may carry some potential risks. First, the drug has been associated with thrombosis and thromboembolic complications in patients with chronic liver disease. This means long-term use may increase the risk of blood clots. Secondly, according to clinical data, adverse reactions such as fever, abdominal pain, nausea, headache, fatigue and peripheral edema may occur after using this drug. In addition, use of avatrombopag in pregnant women may cause harm to the fetus.

Based on the above analysis, long-term use of avatrombopag may not be the best choice for patients with thrombocytopenia. Generally, this drug should only be taken by mouth for a maximum of 5 days. Patients should strictly follow the doctor's instructions when using it and avoid self-medication to prevent adverse consequences. At the same time, it is necessary to pay close attention to the occurrence of adverse reactions and provide timely feedback to the doctor.